# OnCo record indupro-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/indupro-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "indupro-therapeutics" ;
  schema:name "InduPro Therapeutics"@en ;
  schema:alternateName "InduPro"@en ;
  schema:description "InduPro Therapeutics maps which proteins sit side by side on the surface of cancer cells and designs two-armed antibody-drug conjugates that bind such a pair. Its first medicine, for lung and other squamous cancers, entered a phase 1 trial in 2026."@en ;
  schema:url <https://onco.cc/companies/indupro-therapeutics/>, <https://www.induprotx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.induprotx.com/>, <https://www.biospace.com/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-ph-d-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases>, <https://www.induprotx.com/news/indupro-closes-77-million-series-b-financing-and-doses-first-patient-in-phase-1-study-of-lead-oncology-program-idp-001/>, <https://www.induprotx.com/pipeline/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:trials <https://onco.cc/trials/nct07602842/> .